CHANGES IN THE NUMBER OF ACAS BENEFICIARIES SINCE 2015
This chart shows the evolution of the number of ACA beneficiaries since 2015.
2015: 1,943
2016: 2,079
2017: 2,038
2018: 2,141
2019: 2,107
2020: 2,208
2021: 2,408
2022: 2,647
2023: 2,763
2024: 2,742
On 31 December 2024, there was no stock option plan in place for the purchase of Company(1) shares, the last plan having expired in 2021.
The Annual General Meeting of 23 April 2024 gave the Board of Directors the authorisation to carry out free grants of existing shares and/or shares to be issued to employees and corporate officers of the Company and of its French or foreign subsidiaries under the conditions of Article L. 225-197- 2 of the French Commercial Code.
The Annual General Meeting set the period of validity of the authorisation, which may be used on one or more occasions, at 26 months.
The total number of free shares thus granted may not represent more than 0.6% of the share capital recorded on the date of the Board of Directors’ decision.
The number of free shares granted to the Company’s corporate officers may not represent more than 10% of the total number of free shares granted during a financial year pursuant to this resolution.
The Board of Directors will determine the identity of the beneficiaries of the free shares and the number granted to each of them. It will also determine the conditions to be met in order for the shares to fully vest, in particular the financial and non-financial performance conditions.
The financial performance criteria are based on:
The non-financial performance criteria are based on:
The Board of Directors indeed considers that these two types of criteria, assessed over a long period of three financial years and applied to several plans, are complementary, in line with the Group’s objectives and its specificities and likely to promote balanced, continuing growth over the long term. They are exacting but remain a source of motivation for the beneficiaries. The grant of such shares to their beneficiaries, for all or part of the shares granted, will become final provided that the other conditions set at the time of grant are met, at the end of a minimum vesting period of four years.